Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.32 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2594741 | 0.77 | DDR1 (0.34) | — | |
| SCHEMBL21438892 | 0.77 | SLC6A2 (0.32) | EZH2 | |
| SCHEMBL21438922 | 0.76 | HCAR3 (0.41) | P2RX3P2RX2 | |
| SCHEMBL12752155 | 0.75 | PGR (0.39) | — | |
| SCHEMBL850473 | 0.74 | SLC6A2 (0.44) | EZH2 | |
| SCHEMBL14727054 | 0.73 | EZH2 (0.40) | P2RX3P2RX2EZH2 | |
| SCHEMBL21439335 | 0.72 | NOTUM (0.40) | P2RX3P2RX2 | |
| SCHEMBL28487278 | 0.71 | — | — | |
| SCHEMBL35211219 | 0.70 | HTR2A (0.33) | — | |
| SCHEMBL20906148 | 0.69 | NOTUM (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021018194-A1 | HETEROCYCLIC COMPOUNDS AS BCR-ABL INHIBITORS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2021-02-04 | — | — | WO | disclosed |
| EP-3246027-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF CANCER | GlaxoSmithKline LLC (US) | 2017-11-22 | — | — | EP | disclosed |
| US-9649307-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160296518-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2016-10-13 | — | — | US | disclosed |
| US-9446041-B2 | Method of treatment | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| US-9402836-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2016-08-02 | — | — | US | disclosed |
| US-20160074394-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE LLC | 2016-03-17 | — | — | US | disclosed |
| US-9242962-B2 | Method of treatment | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-20150313887-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2015-11-05 | — | — | US | disclosed |
| US-9114141-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150141436-A1 | INDOLES | KIDS2, INC. | 2015-05-21 | — | — | US | disclosed |
| US-8975291-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2015-03-10 | — | — | US | disclosed |
| US-20140256739-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE LLC | 2014-09-11 | — | — | US | disclosed |
| US-8536179-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2013-09-17 | — | — | US | disclosed |
| US-20130053397-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160074394-A1 | METHOD OF TREATMENT | EZH1, EZH2, SUV39H2 | P2RX3 4110/4885P2RX2 3991/4885EZH2 2/4885 |
| US-20150141436-A1 | INDOLES | IDO1, IDO2, INMT | P2RX3 4606/4885P2RX2 4559/4885EZH2 257/4885 |
| US-20140256739-A1 | METHOD OF TREATMENT | EZH1, EZH2, SUV39H2 | P2RX3 4110/4885P2RX2 3991/4885EZH2 2/4885 |
| US-20150313887-A1 | INDOLES | IDO1, IDO2, INMT | P2RX3 4606/4885P2RX2 4559/4885EZH2 257/4885 |
| US-20130053397-A1 | INDOLES | IDO1, IDO2, INMT | P2RX3 4584/4885P2RX2 4563/4885EZH2 239/4885 |
| US-20160296518-A1 | INDOLES | IDO1, IDO2, INMT | P2RX3 4606/4885P2RX2 4559/4885EZH2 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.